JP2016505614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505614A5 JP2016505614A5 JP2015551255A JP2015551255A JP2016505614A5 JP 2016505614 A5 JP2016505614 A5 JP 2016505614A5 JP 2015551255 A JP2015551255 A JP 2015551255A JP 2015551255 A JP2015551255 A JP 2015551255A JP 2016505614 A5 JP2016505614 A5 JP 2016505614A5
- Authority
- JP
- Japan
- Prior art keywords
- branched
- linear
- alkyl
- compound
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 21
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 11
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 0 *C(CCC(*)=C1)C1c1c(*)cc(*)c(F)c1* Chemical compound *C(CCC(*)=C1)C1c1c(*)cc(*)c(F)c1* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750043P | 2013-01-08 | 2013-01-08 | |
| US61/750,043 | 2013-01-08 | ||
| PCT/IL2014/050023 WO2014108899A1 (en) | 2013-01-08 | 2014-01-08 | Fluorinated cbd compounds, compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017198146A Division JP2018065794A (ja) | 2013-01-08 | 2017-10-12 | フッ化ｃｂｄ化合物、それらの組成物および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505614A JP2016505614A (ja) | 2016-02-25 |
| JP2016505614A5 true JP2016505614A5 (enExample) | 2017-02-16 |
| JP6228230B2 JP6228230B2 (ja) | 2017-11-08 |
Family
ID=50272668
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551255A Active JP6228230B2 (ja) | 2013-01-08 | 2014-01-08 | フッ化ｃｂｄ化合物、それらの組成物および使用 |
| JP2017198146A Pending JP2018065794A (ja) | 2013-01-08 | 2017-10-12 | フッ化ｃｂｄ化合物、それらの組成物および使用 |
| JP2019012349A Active JP6952727B2 (ja) | 2013-01-08 | 2019-01-28 | フッ化ｃｂｄ化合物、それらの組成物および使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017198146A Pending JP2018065794A (ja) | 2013-01-08 | 2017-10-12 | フッ化ｃｂｄ化合物、それらの組成物および使用 |
| JP2019012349A Active JP6952727B2 (ja) | 2013-01-08 | 2019-01-28 | フッ化ｃｂｄ化合物、それらの組成物および使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9447019B2 (enExample) |
| EP (1) | EP2943463B1 (enExample) |
| JP (3) | JP6228230B2 (enExample) |
| CN (1) | CN105209424B (enExample) |
| AU (2) | AU2014206036B2 (enExample) |
| CA (1) | CA2935899C (enExample) |
| ES (1) | ES2894836T3 (enExample) |
| MX (1) | MX381719B (enExample) |
| WO (1) | WO2014108899A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014206036B2 (en) | 2013-01-08 | 2017-11-02 | Universidade De Sao Paulo - Usp | Fluorinated CBD compounds, compositions and uses thereof |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| AU2016293387A1 (en) * | 2015-07-16 | 2018-01-25 | Universidade De São Paulo - Usp | Flourinated CBD compounds, compositions and uses thereof |
| WO2021173130A1 (en) | 2020-02-26 | 2021-09-02 | Vitality Biopharma, Inc. | Novel cannabinoid glycosides and uses thereof |
| JP2018528977A (ja) | 2015-09-22 | 2018-10-04 | バイタリティ バイオファーマ インコーポレイテッドＶｉｔａｌｉｔｙ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． | カンナビノイドグリコシドプロドラッグおよび合成の方法 |
| MA43001A (fr) * | 2015-10-16 | 2021-04-07 | Impact Biosciences Corp | Cannabidiol et hu-211 pour le traitement d'une lésion cérébrale traumatique |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| CA3063186A1 (en) | 2017-05-09 | 2018-11-15 | Vitality Biopharma, Inc. | Antimicrobial compositions comprising cannabinoids and methods of using the same |
| EP3630145A4 (en) | 2017-05-31 | 2021-04-07 | Phytecs, Inc. | PHARMACEUTICAL COMPOSITIONS OF CANNABIDIOL AND BETA-CARYOPHYLLENE AND METHOD FOR USING THEM |
| AU2018343256B2 (en) | 2017-09-28 | 2024-09-19 | Harmony Biosciences Management, Inc. | Treatment of Fragile X Syndrome with cannabidiol |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
| US11458109B2 (en) | 2018-12-14 | 2022-10-04 | Zynerba Pharmaceuticals, Inc. | Treatment of 22Q11.2 deletion syndrome with cannabidiol |
| EP4069215A4 (en) | 2019-12-06 | 2024-01-17 | Jlabs Beauty LLC | TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF PREPARING AND USING THE SAME |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| EP4153306A4 (en) | 2020-05-22 | 2024-06-26 | Ilera Derm LLC | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL DISEASES |
| GB2642523A (en) * | 2024-07-12 | 2026-01-14 | Sonas Pharmaceuticals N I Ltd | Novel halogenated cannabinoid derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
| MX2010001242A (es) * | 2007-07-30 | 2010-07-02 | Alltranz Inc | Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos. |
| US20120172339A1 (en) | 2009-07-10 | 2012-07-05 | Northeastern University | Angiogenic resorcinol derivatives |
| HRP20171236T1 (hr) | 2009-08-31 | 2017-10-20 | Zynerba Pharmaceuticals, Inc. | Upotreba prolijekova kanabidiola u topičkoj i transdermalnoj primjeni s mikroiglama |
| WO2012011112A1 (en) * | 2010-07-22 | 2012-01-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Non psychoactive cannabinoids and uses thereof |
| AU2014206036B2 (en) | 2013-01-08 | 2017-11-02 | Universidade De Sao Paulo - Usp | Fluorinated CBD compounds, compositions and uses thereof |
-
2014
- 2014-01-08 AU AU2014206036A patent/AU2014206036B2/en active Active
- 2014-01-08 JP JP2015551255A patent/JP6228230B2/ja active Active
- 2014-01-08 CA CA2935899A patent/CA2935899C/en active Active
- 2014-01-08 US US14/759,689 patent/US9447019B2/en active Active
- 2014-01-08 MX MX2015008766A patent/MX381719B/es unknown
- 2014-01-08 CN CN201480012168.2A patent/CN105209424B/zh active Active
- 2014-01-08 WO PCT/IL2014/050023 patent/WO2014108899A1/en not_active Ceased
- 2014-01-08 ES ES14709750T patent/ES2894836T3/es active Active
- 2014-01-08 EP EP14709750.5A patent/EP2943463B1/en active Active
-
2016
- 2016-08-19 US US15/241,557 patent/US9782360B2/en active Active
-
2017
- 2017-08-01 US US15/666,128 patent/US10441553B2/en active Active
- 2017-10-12 JP JP2017198146A patent/JP2018065794A/ja active Pending
-
2018
- 2018-01-24 AU AU2018200570A patent/AU2018200570B2/en active Active
-
2019
- 2019-01-28 JP JP2019012349A patent/JP6952727B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505614A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2016514159A5 (enExample) | ||
| JP2014526533A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| JP2016506958A5 (enExample) | ||
| EA201591457A8 (ru) | Терапевтические соединения | |
| JP2015537008A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2011105738A5 (enExample) | ||
| JP2013544860A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| JP2011518833A5 (enExample) | ||
| JP2016505637A5 (enExample) | ||
| JP2013532687A5 (enExample) | ||
| JP2014513051A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| AR082620A1 (es) | Compuesto de quinolil amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar una enfermedad mediada por la inhibicion de la quinasa rip2 | |
| JP2014028916A5 (enExample) | ||
| JP2016507575A5 (enExample) | ||
| JP2016503403A5 (enExample) | ||
| JP2017503833A5 (enExample) | ||
| JP2015521156A5 (enExample) | ||
| JP2018530582A5 (enExample) |